title: Monoclonal anti-CD20 Antibody Therapy in Cicatrical Pemphigoid with Oral and Hypopharyngeal Involvement and Related Conditions.
abstract: Mucous membrane pemphigoid is a rare blistering autoimmune disorder that can lead to significant disability. Recently, the monoclonal anti-CD20 antibody rituximab has shown efficacy in pemphigus and pemphigoid, but the data for pemphigoid are relatively sparse. The authors report a series of four patients with severe cicatrical pemphigoid treated with rituximab. All of these patients responded and two of them had a complete remission. Rituximab is a second-line treatment for severe and recalcitrant cicatrical pemphigoid.
authors.affiliation: Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Wollina
authors.forename: Friedemann
authors.initials: F
authors.lastname: Pabst
authors.forename: Heidrun
authors.initials: H
authors.lastname: Kuss
authors.forename: Michaela
authors.initials: M
authors.lastname: Tilp
authors.forename: Juliane
authors.initials: J
authors.lastname: Runge